Document Detail

Association of UGT1A1 Variants and Hyperbilirubinemia in Breast-Fed Full-Term Chinese Infants.
Jump to Full Text
MedLine Citation:
PMID:  25102181     Owner:  NLM     Status:  Publisher    
A retrospective case control study of breast-fed full-term infants was carried out to determine whether variants in Uridine Diphosphate Glucuronosyl Transferase 1A1 (UGT1A1) and Heme Oxygenase-1 (HMOX1) were associated with neonatal hyperbilirubinemia. Eight genetic variants of UGT1A1 and 3 genetic variants of HMOX1 were genotyped in 170 hyperbilirubinemic newborns and 779 controls. Five significant associations with breast-fed hyperbilirubinemia were detected after adjusting for gender, birth season, birth weight, delivery mode, gestational age and False Discovery Rate (FDR) correction: the dominant effect of rs887829 (c-364t) (Odds Ratio (OR): 0.55; 95% Confidence Interval (CI): 0.34-0.89; p = 0.014), the additive effect of (TA)n repeat (OR: 0.59; 95%CI: 0.38-0.91; p = 0.017), the dominant effect of rs4148323 (Gly71Arg, G211A) (OR: 2.02; 95%CI: 1.44-2.85; p = 5.0×10-5), the recessive effect of rs6717546 (g+914a) (OR: 0.30; 95%CI: 0.11-0.83; p = 0.021) and rs6719561 (t+2558c) (OR: 0.38; 95%CI: 0.20-0.75; p = 0.005). Neonates carrying the minor allele of rs887829 (TA)n repeat had significantly lower peak bilirubin than wild types, while the minor allele carriers of rs4148323 had significantly higher peak bilirubin than wild types. No association was found in HMOX1. Our findings added to the understanding of the significance of UGT1A1 in association with neonatal hyperbilirubinemia in East Asian population. Additional studies were required to investigate the mechanisms of the protective effects.
Youyou Zhou; San-Nan Wang; Hong Li; Weifeng Zha; Xuli Wang; Yuanyuan Liu; Jian Sun; Qianqian Peng; Shilin Li; Ying Chen; Li Jin
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-7
Journal Detail:
Title:  PloS one     Volume:  9     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2014  
Date Detail:
Created Date:  2014-8-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  -    
Other Details:
Languages:  ENG     Pagination:  e104251     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2014 Zhou et al
Received Day: 6 Month: 4 Year: 2014
Accepted Day: 20 Month: 6 Year: 2014
collection publication date: Year: 2014
Electronic publication date: Day: 7 Month: 8 Year: 2014
Volume: 9 Issue: 8
E-location ID: e104251
PubMed Id: 25102181
ID: 4125195
Publisher Id: PONE-D-14-14986
DOI: 10.1371/journal.pone.0104251

Association of UGT1A1 Variants and Hyperbilirubinemia in Breast-Fed Full-Term Chinese Infants Alternate Title:UGT1A1 Variants and Breast-Fed Hyperbilirubinemia
Youyou Zhou1
San-nan Wang2
Hong Li3
Weifeng Zha2
Xuli Wang2
Yuanyuan Liu2
Jian Sun3
Qianqian Peng1
Shilin Li1
Ying Chen3
Li Jin1*
Bing-Hua Jiangedit1 Role: Editor
1Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China
2Department of Neonatology, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, China
3Center for Reproduction and Genetics and Suzhou Maternal-Child Medical Center, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, China
Thomas Jefferson University, United States of America
Correspondence: * E-mail:
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived and designed the experiments: YZ SW YC LJ. Performed the experiments: YZ WZ XW YL JS. Analyzed the data: YZ WZ QP. Contributed reagents/materials/analysis tools: HL SL. Contributed to the writing of the manuscript: YZ SW YC LJ.


Neonatal jaundice is a physiological and generally benign phenomenon. However, excessively high bilirubin concentration may cause permanent neural damage in newborns, i.e., “chronic bilirubin encephalopathy” or kernicterus [1]. Genetic and environmental factors contribute to the development of hyperbilirubinemia and the impact of genetic variation on this condition is increasingly recognized [2]. In particular, variants in the rate limiting enzymes in the bilirubin metabolism pathway may be associated with hyperbilirubinemia.

Uridine Diphosphate Glucuronosyl Transferase 1A1 (UGT1A1) is the key enzyme for bilirubin conjugation while unconjugated bilirubin is the main cause of hyperbilirubinemia [3]. A (TA)n repeat located in the promoter region of the gene, UGT1A1, is found to be associated with the transcriptional activity [4]. In Caucasian newborns, the minor allele homozygote of this variant significantly increases bilirubin concentration during the first 2 days of life [5]. In addition, when the minor allele homozygote or heterozygote combined with Glucose-6-Posphate Dehydrogenase (G6PD) deficiency, the incidence of hyperbilirubinemia is increased [6]. However, in East Asian populations, such as Japanese and Chinese, the minor allele of rs4148323 (Gly71Arg, G211A) in exon 1, but not (TA)n repeat, is found to be associated with neonatal hyperbilirubinemia [7], [8], [9].

Heme Oxygenase-1 (HMOX1) is another key enzyme in bilirubin metabolism pathway. It catalyzes the first and the rate-controlling step of heme degradation and generates biliverdin that is converted into bilirubin via biliverdin reductase [3]. A (GT)n dinucleotide repeat is located in the promoter region of HMOX1, and the repeat is associated with transcriptional activity [10]. However, little is known regarding the clinical impact of the HMOX1 variants on neonatal hyperbilirubinemia.

Exclusive breastfeeding is defined as a risk factor for development of severe hyperbilirubinemia [11], but it is the reference normative standard for infant feeding and nutrition as well [12]. Since East Asian ethnicity is considered as a high risk factor [11], some studies have been carried out in Japan and China Taiwan to explore the genetic factors associated with breast-fed neonatal hyperbilirubinemia [13], [14], [15]. None was done in China mainland. Therefore, we performed an exploratory study on association of variants of the two genes and hyperbilirubinemia in breast-fed full-term Chinese infants.

Materials and Methods

This study retrospectively enrolled infants born between February and October in 2008 from The Municipal Hospital in Suzhou, China. Eligible infants were exclusively breast-fed, had an estimated gestational age of 37 weeks or above, had a birth weight of 2500 grams or above, and had no major abnormalities.

Every morning, transcutaneous bilirubin (TcB) was measured on the forehead of each neonate before discharge. Five transcutaneous bilirubinometers, including 3 KONICA MINOLTA JM-103 and 2 local branded were randomly used by the neonatologists. The hospital has adopted a discharge policy of 72 hours or above for newborns delivered vaginally and 120 hours or above for newborns delivered by cesarean section. Once the infant was discharged, no TcB was measured any more. Peak TcB of each neonate before discharge was reviewed.

According to China guideline in Practical Neonatology[16] and Practical Pediatrics[17], neonates were diagnosed as hyperbilirubinemia when their maximum TcB exceeded 12.9 mg/dL (221 µmol/L) on day 3 or later before they were discharged. Once the infants developed high concentration of bilirubin before day 3 or the pathological cause of hyperbilirubinemia was confirmed,infants would be transferred to the Neonatal Unit and excluded from our study. Otherwise, infants diagnosed as hyperbilirubinemia would receive phototherapy and remain in our study as cases. Newborns whose peak TcB during birth hospitalization stay were less than or equal to 12.9 mg/dL served as controls.

Blood samples for genotyping were obtained from surplus filter papers which were kept at 4°C for about one year after routine newborn screening.

The study was approved by both Suzhou Municipal Hospital Reproductive Medicine Ethics Committee and the Ethics Committee of Institutes of Biomedical Sciences. Since the data were analyzed anonymously, the filter paper was obtained from a standard screening procedure, and the TcB measurement was a completely noninvasive routine clinical assessment, both committees approved a waiver of written consent.

Each filter paper was placed in an Eppendorf tube, fully soaked in 1×PBS (pH = 8.0), and incubated in boiled water for 5 minutes. After a quick spin, the supernatant was transferred to a new tube, washed with absolute ethanol, centrifuged at 13,000 rpm for 10 minutes, and the supernatant was discarded. After a second wash with 70% ethanol, the precipitate was air dried. After resuspension in distilled H2O, the DNA extract was kept at −20°C until further use.

A final set of 11 genetic variants was selected for genotyping based on (1) functional significance, (2) tagging Single Nucleotide Polymorphisms (SNP) located at least 5 kb upstream and 2 kb downstream of HMOX1 (chr22: 34102087–34122194) and UGT1A1 (chr2:234328658..234348684), respectively [HapMap Data Release #27 (phase II+III), Feb 09, on NCBI B36 assembly, dbSNP b126], selected from the HapMap Han Chinese (CHB) population based on r2>0.8 and minor allele frequency (MAF)>0.1; (3) either G/A or C/T SNP combination due to the limitation of the SNPstream (Beckman Coulter) platform. These variants were able to capture 7 of 9 (78%) polymorphisms of HMOX1, 18 of 22 (82%) polymorphisms of UGT1A1. Information of the variants and the genotyping assays are listed in Table 1.

(TA)n repeat and (GT)n repeat were amplified by a duplex PCR whose forward primers were labeled with FAM respectively. The products were electrophoresed on a Genetics Analyzer 3730xl (Applied Biosystems, Foster City, USA) according to the manufacturer's manual. Nine SNPs were genotyped using a GenomeLab SNPstream Genotyping System (Beckman Coulter Inc., Fullerton, California, USA) following the manufacturer's standard procedure. To ensure the reliability and the reproducibility of the genotyping, about 3–5% samples were repeated for each assay. The overall genotyping call rate was 95%, and concordance rate was higher than 99%.

Hardy-Weinberg equilibrium (HWE) for the (GT)n repeat of HMOX1 was performed using an exact test [18]. HWE for other variants, including bi-allelic-grouped (TA)n repeat of UGT1A1 were examined by Fisher's exact test.

Haplotypes and their frequencies were inferred using PHASE version 2.1.1 software ( The Haploview program ( was adopted to identify block structures, and to calculate |D′| and r2 to measure linkage disequilibrium (LD).

Continuous variables and categorical variables were compared by t test and Pearson's χ2 test, respectively. Univariate logistic regression analysis was performed to compute unadjusted and adjusted ORs with 95% CIs. Peak TcB comparison according to genotypes were examined by t test and adjusted by covariance (ANOCVA). All analyses were performed with SPSS version 16.0 software (SPSS Inc, Chicago, IL, USA). A two-sided probability value of <0.05 was considered statistically.

To avoid assumptions regarding the models of inheritance, additive, dominant, and recessive models for each bi-allelic polymorphism were assessed by SNPstats ( The best-fitting inheritance model for each polymorphism was selected based on the lowest Akaike information criteria (AIC) [19]. For multiple hypotheses test, False Discovery Rate (FDR) was applied.


Initially, we have enrolled 331 hyperbilirubinemic infants. After controlling the filter paper's quality for further DNA analysis, only 170 hyperbilirubinemia participants left. After controlling the DNA quality, seven hundred and seventy-nine control participants were chosen at random within matching criteria of gender, delivery mode and birth season. The characteristics of the participants are summarized in Table 2. Cases and controls were comparable in gender, delivery mode, birth season, birth weight and gestational age. Peak TcB before discharge was significantly higher in hyperbilirubinemic infants than controls. The highest peak TcB was 18.0 mg/dL and 12.9 mg/dL in hyperbilirubinemic and control groups, respectively.

All hyperbilirubinemic infants' bilirubin values dropped to 12.9 mg/dL or even less after phototherapy. None received exchange transfusion, none developed encephalopathy.

The counts of genotypes at all variants are presented in Table 3. The average call rate was 95%. Among the 11 genotyped variants, rs1018124 (80%), rs4663972 (89%) and rs6717546 (94%)'s call rate was lower than 95%. None of the variants showed significant deviation from HWE, except for rs2071749 (p = 0.04).

Additionally, we found 3 (TA)8 alleles in the (TA)n repeat. Because of its low frequency and reported decreasing promoter activity with an increasing number of (TA)n repeat [20], we merged (TA)8 into (TA)7 for further analysis. Therefore, (TA)n repeat was considered as bi-allelic variant.

LD results are shown in Table 4. Strong pairwise LD was observed in several pairs (each |D′|>0.8) within HMOX1 and UGT1A1. But higher r2 values (each r2>0.5) only existed between rs887829 and (TA)n repeat (r2 = 0.864), rs6717546 and rs6719561 (r2 = 0.508) in UGT1A1. An LD block structure was observed within HMOX1, including rs9607267 and rs2071749 ((GT)n repeat was not analyzed). No block was found in UGT1A1.

The distributions of (GT)n repeat in HMOX1 promoter in both case and control groups are shown in Figure 1. Both groups had four modes, located at 23, 30, 34 and 36, respectively. Using the classification defined by Yamada et al., the allele was classified into three classes according to the repeat length, namely, short alleles (S: <27 GT), middle alleles (M: 27–32 GT), and long alleles (L: ≥33 GT) [10]. The distributions of the genotypes are listed in Table 3. Neither genotypes nor allele distribution had significant difference between case and control groups. Based on previous publication, six genotypes could be merged into 2 groups: Group 1 (SS_SM) and Group 2 (SL_MM_ML_LL). Obviously, the HMOX1 expression of Group 1 was expected to be higher than that of Group 2 [21]. However, we did not find an association between merged groups and neonatal hyperbilirubinemia (Table 3).

The associations of other variants are listed in Table 3. Distribution of genotypes of rs887829 (c-364t), rs4148323, rs6717546 (g+914a) and rs6719561 (t+2558c) in UGT1A1 showed significant differences between case and control groups. Allele distributions of these variants, plus (TA)n repeat, were associated with hyperbilirubinemia too. After controlling gender, birth season, birth weight, delivery mode and gestational age, the minor allele of rs4148323 was found to be a risk factor of hyperbilirubinemia (Odds Ratio (OR): 1.75; 95% Confidence Interval (CI): 1.32–2.31; p = 8.0×10−5); whereas, the minor alleles of the remaining variants were shown to be protective factors: rs887829 (OR: 0.61; 95%CI: 0.39–0.94; p = 0.027) and (TA)n repeat (OR: 0.58; 95%CI: 0.37–0.90; p = 0.015) are two variants at the promoter region and are 310 nucleotides apart from each other; rs6717546 (OR: 0.70; 95%CI: 0.53–0.93; p = 0.015) and rs6719561 (OR: 0.68; 95%CI: 0.52–0.89; p = 0.005) are two tag SNPs located in 914 and 2558 nucleotides downstream of UGT1A1, respectively. After applying the FDR adjustment for multiple testing, only rs887829 lost statistically significance.

No variant in HMOX1 was found to be associated with neonatal hyperbilirubinemia, neither was the LD block found in this gene (data not shown).

The result of best-fitting inheritance model analysis of associated variants was shown in Table 5. All of the five variants were associated with hyperbilirubinemia in its best-fitting inheritance model, and remained significantly after controlling gender, birth season, birth weight, delivery mode and gestational age and the FDR correction: the dominant effect of rs887829 (OR: 0.55; 95%CI: 0.34–0.89; p = 0.014), the additive effect of (TA)n repeat (OR: 0.59; 95%CI: 0.38–0.91; p = 0.017), the dominant effect of rs4148323 (OR: 2.02; 95%CI: 1.44–2.85; p = 5.0×10−5), the recessive effect of rs6717546 (OR: 0.30; 95%CI: 0.11–0.83; p = 0.021) and rs6719561 (OR: 0.38; 95%CI: 0.20–0.75; p = 0.005) on neonatal jaundice.

LD test data shown in Table 4 demonstrated low r2 between rs4148323 and any of the aforementioned protective variants (each r2<0.08). Correspondingly, PHASE results also showed the frequency that the minor alleles of rs4148323 and rs887829 located on the same chromosome was 0.0019, as low as those of rs4148323 and (TA)n repeat (frequency = 0.0018), rs4148323 and rs6717546 (frequency = 0.0188), and rs4148323 and rs6719561 (frequency = 0.0142). Furthermore, the frequency of all the minor alleles appearing on the same chromosome was 0. We speculated that the risk effect of the minor allele of rs4148323 and the protective effects of the minor alleles of the protective variants worked separately on the development of neonatal jaundice.

Comparisons of peak TcB according to UGT1A1 genotypes were shown in Table 6. A general (additive) model was assumed for each polymorphism. The minor allele carriers (including both homozygous and heterozygous carriers) of rs4148323 had significant higher peak TcB than wild types (p = 2.9×10−7). On the other hand, the minor allele carriers of rs887829, (TA)n repeat, rs6717546, or rs6719561 had significant lower peak TcB than wild types (p = 0.002, 0.001, 0.022 and 0.04, respectively). No difference was found in HMOX1 genotypes. After applying the FDR adjustment, rs887829, (TA)n and rs4148323 retained statistical significance.


Breastfeeding has been shown to have several advantages for infants, mothers, and families [12]. However, there is a strong association between breastfeeding and an increased risk of hyperbilirubinemia [11]. Since the etiology of breast-fed hyperbilirubinemia is unclear, associated factors should be systematically studied, especially in East Asian population, which is classified as a risk factor [11].

HMOX1 catalyzes the rate-limiting step in heme degradation. Based on the functional study, we suspected that shorter repeat carriers may have higher bilirubin level. Considering the distribution pattern of (GT)n repeat, we tried more bi-allele definitions (S and L) other than the Yamada classification [10], including: <20 and ≥20, <23 and ≥23, <24 and ≥24 and <27 and ≥27, ≤32 and >32, ≤35 and >35. Unfortunately we did not find any association between (GT)n repeat and hyperbilirubinemia. We hypothesized that the ‘short’ and ‘long’ cut-off value of (GT)n repeat may be a grey zone instead of a single value.

The investigation of UGT1A1 showed that rs4148323 (211G>A, Gly71Arg), located in the first exon, was a risk factor in neonatal hyperbilirubinemia, and was associated with higher peak TcB during hospitalization stay. Previous functional studies have shown that UGT1A1 enzyme activity of the minor allele carriers was significantly lower than that of major allele carriers [22], [23].

(TA)n repeat in the promoter of UGT1A1 is another extensively studied variant. Published functional studies have shown that the transcriptional activity of long repeat is significantly lower than that of short repeat [4], [20]. But the effect of long repeat on neonatal jaundice is not consistent. Risk effect has been observed in some Caucasian populations but not in Asian populations [5], [6], [7], [8], [24].Our study found the association between (TA)n repeat and neonatal jaundice in an Asian population. Surprisingly, the long repeat appeared to be a protective factor and was associated with lower peak TcB during hospitalization stay, which was on the opposite of the functional study result.

Indeed, one recent association study between UGT1A1 and neonatal jaundice in breast-fed Japanese newborns illustrated that heterozygous (TA)7 mutation significantly decreased the risk of hyperbilirubinemia (OR: 0.37; 95%CI: 0.15–0.89; p = 0.027) [15]. Another study in Taiwan showed the mean values of peak bilirubin in each (TA)n genotype were significantly different: LL<SL<SS (p = 0.040) [14]. Furthermore, two meta-analysis studies also showed the protective effect of long repeat in two East Asian populations: Chinese and Japanese. Yang et al. found the frequency of (7/7+6/7) in control group was significantly higher than that of the hyperbilirubinemic group in both Chinese and Japanese newborns. The OR (95%CI) were 0.59 (0.36–0.96) and 0.15 (0.04–0.51), respectively [25]. Later, Long et al. calculated the OR (95%CI) of (7/7+6/7) as 0.02 (0.14–0.42), the OR (95%CI) of (TA)7 as 0.13 (0.04–0.42) [26].

In fact, it was found that longer (TA)n repeat frequency was highest in African (49.5%), subsequently followed by European (38.7%) and Asian (16%) [20].And the hyperbilirubinemia guideline published by American Academy of Pediatrics (AAP) illustrated African origin was a protective factor whereas East Asian ethnicity was a risk factor for development of severe hyperbilirubinemia [11]. Taking these two opinions into consideration, we argued that (TA)n longer repeat working as a protective factor for neonatal hyperbilirubinemia was more reasonable than a risk factor, although the mechanism (TA)n longer repeat protect newborns from hyperbilirubinemia may be totally different from the known functional study. Due to the unexplained contradiction, further case control studies in East Asian population and functional analysis may help to disclose the mechanism.

Rs887829 (c-364t) is another variant located in the promoter of UGT1A1, 310 bp away from (TA)n repeat. Strong LD between these two sites was found in our population (D′ = 0.937, r2 = 0.864), similar to the observation in a Japanese population and an African population respectively [27], [28]. There are no published functional studies on rs887829. One in vitro study showed that rs887829 did not affect the transcriptional activity of UGT1A1 (unpublished data). We proposed that the protective effect of rs887829 may be due to the strong LD between this site and (TA)n repeat.

Additionally, two tag SNPs, rs6717546 (g+914a) and rs6719561 (t+2558c), both located in the 3′ of UGT1A1, were associated with neonatal breast-fed hyperbilirubinemia too. So far there is no publication on these two sites. The only relative result we found was on rs4148329 (c+857t), which could be captured by rs6717546. That study showed significantly smaller bilirubin change before day 5 was observed for neonates who were homozygous for the minor allele versus those with wild-type (p<0.003) [29].In other words, rs4148329 minor allele carriers' bilirubin increased slowly so that they were at low risk for development of hyperbilirubinemia. That result of rs4148329 was consistent with ours on rs6717546. Unfortunately, no functional study was done on rs4148329. Therefore we proposed that the protective effects may be due to the strong LD with other potential functional sites.

This study has three limitations. (1) Due to short birth hospitalization stay, daily TcB measurement was normally stopped after day 4 for vaginal delivery and day 5 for cesarean delivery. We were not sure that some may become hyperbilirubinemia after discharge. But it is known that peak bilirubin normally reaches on day 4 and day 5, after that, the bilirubin either maintains or drops gradually [30], [31], [32]. Besides, short hospitalization stay is a common problem worldwide, hospitalization stay is even shorter in some foreign countries. Therefore, some published papers adopted data on day 3 or even before day 3 [13], [14]. (2) The diagnostic method our hospital used is different from AAP guidelines. Taking 12.9 mg/dL as the threshold from day 3 onwards is more stringent than the 95th centiles in Bhutani's nomogram from 72 hours onwards. This is probably due to the high risk of the ethnicity. (3) Number of cases is small. Although our case number was higher than two recently published breast-fed hyperbilirubinemia association studies [14], [15], and we recruited controls more than four times of cases to increase the statistical analysis power, the power of this study might be limited due to the small case number.


Our study provides important new information on the association between genetic factors and breast-fed hyperbilirubinemia. Genotyping of UGT1A1 may be a supplementary method to predict the development of hyperbilirubinemia in breast-fed full-term Chinese infants. Because of exploratory nature of our study and relatively limited number of examined subjects and variants, our conclusions should be validated in larger prospective trials. In addition, further studies were required to investigate the mechanisms of the protective effects of the variants.

We would like to thank the participants.

1. Johnson L,, Bhutani VK, (Year: 2011) The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol35: 101–11321641482
2. Watchko JF,, Lin Z, (Year: 2010) Exploring the genetic architecture of neonatal hyperbilirubinemia. Semin Fetal Neonatal Med15: 169–17520022574
3. Dennery PA,, Seidman DS,, Stevenson DK, (Year: 2001) Neonatal hyperbilirubinemia. N Engl J Med344: 581–59011207355
4. Bosma PJ,, Chowdhury JR,, Bakker C,, Gantla S,, de Boer A,, et al. (Year: 1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med333: 1171–11757565971
5. Bancroft JD,, Kreamer B,, Gourley GR, (Year: 1998) Gilbert syndrome accelerates development of neonatal jaundice. J Pediatr132: 656–6609580766
6. Kaplan M,, Renbaum P,, Levy-Lahad E,, Hammerman C,, Lahad A,, et al. (Year: 1997) Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A94: 12128–121329342374
7. Maruo Y,, Nishizawa K,, Sato H,, Doida Y,, Shimada M, (Year: 1999) Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism. Pediatrics103: 1224–122710353933
8. Huang CS,, Chang PF,, Huang MJ,, Chen ES,, Hung KL,, et al. (Year: 2002) Relationship between bilirubin UDP-glucuronosyl transferase 1A1 gene and neonatal hyperbilirubinemia. Pediatr Res52: 601–60512357057
9. Sun G,, Wu M,, Cao J,, Du L, (Year: 2007) Cord blood bilirubin level in relation to bilirubin UDP-glucuronosyltransferase gene missense allele in Chinese neonates. Acta Paediatr96: 1622–162517888052
10. Yamada N,, Yamaya M,, Okinaga S,, Nakayama K,, Sekizawa K,, et al. (Year: 2000) Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet66: 187–19510631150
11. AAP (Year: 2004) American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics114: 297–31615231951
12. AAP (Year: 2012) American Academy of Pediatrics Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics129: e827–84122371471
13. Chang PF,, Lin YC,, Liu K,, Yeh SJ,, Ni YH, (Year: 2011) Risk of hyperbilirubinemia in breast-fed infants. J Pediatr159: 561–56521592495
14. Chou HC,, Chen MH,, Yang HI,, Su YN,, Hsieh WS,, et al. (Year: 2011) 211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice. Pediatr Res69: 170–17420975617
15. Sato H,, Uchida T,, Toyota K,, Kanno M,, Hashimoto T,, et al. (Year: 2013) Association of breast-fed neonatal hyperbilirubinemia with UGT1A1 polymorphisms: 211G>A (G71R) mutation becomes a risk factor under inadequate feeding. J Hum Genet58: 7–1023014115
16. Jin H, Huang D, Guan X, editors (1997) Practical Neonatology. 2nd ed. Beijing: People's Medical Publishing House. 1078 p.
17. Hu Y, Wu R, Jiang Z, editors (1996) Practical Pediatrics. 6th ed. Beijing: People's Medical Publishing House. 1356 p.
18. Guo SW,, Thompson EA, (Year: 1992) Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics48: 361–3721637966
19. Sole X,, Guino E,, Valls J,, Iniesta R,, Moreno V, (Year: 2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics22: 1928–192916720584
20. Beutler E,, Gelbart T,, Demina A, (Year: 1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism. Proc Natl Acad Sci US A95: 8170–8174
21. Lin R,, Wang X,, Wang Y,, Zhang F,, Fu W,, et al. (Year: 2009) Association of polymorphisms in four bilirubin metabolism genes with serum bilirubin in three Asian populations. Hum Mutat30: 609–61519243019
22. Aono S,, Adachi Y,, Uyama E,, Yamada Y,, Keino H,, et al. (Year: 1995) Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet345: 958–9597715297
23. Aono S,, Yamada Y,, Keino H,, Hanada N,, Nakagawa T,, et al. (Year: 1993) Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II. Biochem Biophys Res Commun197: 1239–12448280139
24. Zhou YY,, Lee LY,, Ng SY,, Hia CP,, Low KT,, et al. (Year: 2009) UGT1A1 haplotype mutation among Asians in Singapore. Neonatology96: 150–15519325249
25. Yang L,, Ding J,, Zhou W, (Year: 2010) Association between polymorphisms of UDP-glucuonosyltransferase 1A1 gene and hyperbilirubinemia in neonates: a meta-analysis Chinese Journal of Evidence -Based Pediatrics. 5: 335–348
26. Long J,, Zhang S,, Fang X,, Luo Y,, Liu J, (Year: 2011) Association of neonatal hyperbilirubinemia with uridine diphosphate-glucuronosyltransferase 1A1 gene polymorphisms: Meta-analysis. Pediatr Int53: 530–54021342357
27. Sai K,, Saeki M,, Saito Y,, Ozawa S,, Katori N,, et al. (Year: 2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther75: 501–51515179405
28. Horsfall LJ,, Zeitlyn D,, Tarekegn A,, Bekele E,, Thomas MG,, et al. (Year: 2011) Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet75: 236–24621309756
29. Hanchard NA,, Skierka J,, Weaver A,, Karon BS,, Matern D,, et al. (Year: 2011) UGT1A1 sequence variants and bilirubin levels in early postnatal life: a quantitative approach. BMC Med Genet12: 5721513526
30. Wei K (2000) Neonatal Jaundice. In: Wang M, editor. Pediatrics: Neonates and Neonatal Diseases. Beijing: People's Medical Publishing House. pp. 117–119.
31. De Luca D,, Jackson GL,, Tridente A,, Carnielli VP,, Engle WD, (Year: 2009) Transcutaneous bilirubin nomograms: a systematic review of population differences and analysis of bilirubin kinetics. Arch Pediatr Adolesc Med163: 1054–105919884597
32. Yu ZB,, Dong XY,, Han SP,, Chen YL,, Qiu YF,, et al. (Year: 2011) Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants. Eur J Pediatr170: 185–19120814696


[Figure ID: pone-0104251-g001]
doi: 10.1371/journal.pone.0104251.g001.
Figure 1  Distribution of (GT)n repeat of HMOX1.

[TableWrap ID: pone-0104251-t001] doi: 10.1371/journal.pone.0104251.t001.
Table 1  Genotyped variants and genotyping assays.
Variant assay pirmers oligo(5′->3′)
rs6717546 SNPstream(GA) GA5U [gene: TTCATTGCGTGTGCATGC]
rs6719561 SNPstream(CT) CT9U [gene: TGGCTGGAACACATTCTGT]
rs4663972 SNPstream(CT) CT9U [gene: TGGCTGGAACACATTCTGT]
rs9607267 SNPstream(CT) CT10U [gene: TGGGGTTCAGAATAGGCC]

*These were (potential) functional variants from published (and unpublished) studies.

[TableWrap ID: pone-0104251-t002] doi: 10.1371/journal.pone.0104251.t002.
Table 2  Characteristics of hyperbilirubinemic patients and controls.
Variable Case Control p
(n = 170) (n = 779)
Male 89(52.4%) 421(54.0%) 0.69
Delivery mode,n(%)
Vaginal 86(50.6%) 412(52.9%) 0.76
Cesarean 74(43.5%) 330(42.4%)
Forceps 10(5.9%) 37(4.7%)
Birth season,n(%)
Winter (Feb,Mar) 21(12.4%) 96(12.3%) 0.77
Spring and Autumn (Apr,May,Sep,Oct) 106(62.4%) 465(59.7%)
Summer (Jun,Jul,Aug) 43(25.3%) 218(28.0%)
Birth weight,gram (mean±standard deviation)* 3437.4±415.8 3423.8±435.1 0.72
Gestational age, day (mean±standard deviation) 276.7±8.5 277.5±8.4 0.28
Peak TcB, mg/dL (mean±standard deviation) 14.7±1.1 10.4±2.0 2.1×10−143

*Fifteen cases and 78 controls had missing data.

[TableWrap ID: pone-0104251-t003] doi: 10.1371/journal.pone.0104251.t003.
Table 3  Variations in UGT1A1 and HMOX1 genes in breast-fed newborns with hyperbilirubinemic patients and control subjects.
Gene Variant Case Control p(genotype) p(allele) OR(95%CI)a p(allele)b OR(95%CI)b
m/m M/m M/M MAF HWE p m/m M/m M/M MAF HWE p
UGT1A1 rs887829 2 20 141 0.074 0.2 8 162 597 0.116 0.49 0.035 0.025 0.61(0.39–0.94) 0.027 0.61(0.39–0.94)
(TA)n 1 22 146 0.071 0.58 13 154 604 0.117 0.38 0.054 0.014 0.58(0.37–0.90) 0.015d 0.58(0.37–0.90)
rs4148323 8 73 85 0.268 0.17 20 220 510 0.173 0.61 2.0×10−4 7.0×10−5 1.75(1.32–2.31) 8.0×10−5d 1.75(1.32–2.31)
rs1018124 1 41 94 0.158 0.2 23 206 394 0.202 0.62 0.137 0.095 0.74(0.52–1.06) 0.095
rs6717546 4 65 91 0.228 0.07 58 318 357 0.296 0.29 0.023 0.015 0.70(0.53–0.93) 0.015d 0.70(0.53–0.93)
rs11563250 3 36 128 0.126 0.73 19 203 533 0.16 1 0.287 0.12 0.76(0.53–1.08) 0.12
rs6719561 10 71 77 0.288 0.33 111 330 301 0.372 0.21 0.01 0.005 0.68(0.52–0.89) 0.005d 0.68(0.52–0.89)
rs4663972 1 38 115 0.13 0.47 13 188 491 0.155 0.38 0.43 0.271 0.82(0.57–1.17) 0.271
HMOX1 rs9607267 39 79 48 0.473 0.54 157 389 217 0.461 0.51 0.647 0.686 1.05(0.83–1.33) 0.631
rs2071749 15 63 84 0.287 0.56 42 314 384 0.269 0.04 0.212 0.507 1.09(0.84–1.43) 0.507
(GT)nc SS 41 group1 0.08 SS 176 group1 0.08
SM 60 (SS_SM) SM 297 (SS_SM) 6-grouped: L:0.940 1.02(0.68–1.51) 0.94
SL 19 group2 SL 80 group2 0.931 M:0.727 0.96(0.74–1.23) 0.727
MM 30 (SL_MM_ MM 141 (SL_MM_ 2-grouped: S:/ 1 /
ML 16 ML_LL) ML 65 ML_LL) 0.804
LL 1 LL 10

m:minor allele; M:major allele; MAF:minor allele frequency; HWE p:Hardy-Weinberg equilibrium test p value; OR: odds ratio; CI: confidence interval.

aProvided that OR of M allele was 1.

bAdjusted for gestational age, birth season, delivery mode, birth weight and gender. OR was provided when p value was below 0.05.

c(GT)n repeat was classified into 3 groups (S\M\L). Provided that OR of S allele was 1.

dRetained significance after the FDR adjustment (<0.05×4/11).

[TableWrap ID: pone-0104251-t004] doi: 10.1371/journal.pone.0104251.t004.
Table 4  Linkage Disequilibrium.
r2 HMOX1 rs9607267 rs2071749
rs9607267 0.976
rs2071749 0.308
UGT1A1 rs887829 (TA)n rs4148323 rs1018124 rs6717546 rs11563250 rs6719561 rs4663972
rs887829 0.937 1 1 0.588 0.394 0.642 0.582
(TA)n 0.864 0.829 0.686 0.608 0.663 0.641 0.472
rs4148323 0.028 0.02 0.728 0.751 0.737 0.766 0.925
rs1018124 0.029 0.014 0.032 0.701 0.547 0.696 0.285
rs6717546 0.017 0.018 0.054 0.286 0.936 0.852 0.785
rs11563250 0.003 0.01 0.023 0.216 0.377 0.789 1
rs6719561 0.088 0.088 0.077 0.195 0.508 0.199 0.92
rs4663972 0.007 0.005 0.035 0.058 0.259 0.031 0.239

r2>0.5 was shown in bold; |D′|>0.8 was shown in bold.

[TableWrap ID: pone-0104251-t005] doi: 10.1371/journal.pone.0104251.t005.
Table 5  Estimated effects of selected variants on hyperbilirubinemia.
Variant Best-fitting inheritance model OR (95% CI) p-value OR (95% CI)a p-valuea
rs887829 Dominant 0.55 (0.34–0.89) 0.0097b 0.55 (0.34–0.89) 0.014b
(TA)n Additive 0.59 (0.38–0.91) 0.011b 0.59 (0.38–0.91) 0.017b
rs4148323 Dominant 2.03 (1.44–2.85) 1×10−4b 2.02 (1.44–2.85) 5.0×10−5b
rs6717546 Recessive 0.30 (0.11–0.83) 0.0065b 0.30 (0.11–0.83) 0.021b
rs6719561 Recessive 0.38 (0.20–0.75) 0.0018b 0.38 (0.20–0.75) 0.005b

aAdjusted for gender, birth season, birth weight, delivery mode and gestational age.

bRetained significance after the FDR adjustment (<0.05×5/11).

[TableWrap ID: pone-0104251-t006] doi: 10.1371/journal.pone.0104251.t006.
Table 6  Comparison of peak TcB between different genotypes.
Gene Variant n peak TcB, mg/dL p pa
(mean±standard deviation)
rs887829 m/m+M/m 192 10.7±2.4 0.002 0.002b
M/M 738 11.3±2.5
(TA)n m/m+M/m 190 10.7±2.4 0.001 0.001b
M/M 750 11.3±2.5
rs4148323 m/m+M/m 321 11.8±2.3 2.4×10−7 2.9×10−7b
M/M 595 10.9±2.5
rs1018124 m/m+M/m 271 10.9±2.6 0.052 0.055
M/M 488 11.3±2.5
rs6717546 m/m+M/m 445 11.0±2.6 0.02 0.022
M/M 448 11.4±2.4
rs11563250 m/m+M/m 261 11.1±2.5 0.229 0.246
M/M 661 11.3±2.5
rs6719561 m/m+M/m 522 11.1±2.5 0.048 0.04
M/M 378 11.4±2.4
rs4663972 m/m+M/m 240 11.1±2.6 0.268 0.323
M/M 606 11.3±2.5
(GT)n group1 574 11.2±2.5 0.893 0.77
group2 362 11.2±2.5
rs9607267 m/m+M/m 664 11.2±2.5 0.753 0.934
M/M 265 11.2±2.4
rs2071749 m/m+M/m 434 11.2±2.5 0.488 0.671
M/M 468 11.3±2.5

m:minor allele; M:major allele.

aAdjusted for gestational age, birth season, delivery mode, birth weight and gender.

bRetained significance after the FDR adjustment (<0.05×3/11).

Article Categories:
  • Research Article
Article Categories:
  • Biology and Life Sciences
    • Genetics
      • Genetics of Disease
        • Genetic Predisposition
      • Human Genetics
        • Genetic Association Studies
      • Molecular Genetics
Article Categories:
  • Medicine and Health Sciences
    • Clinical Genetics
    • Pediatrics
      • Neonatology
        • Breast Feeding

Previous Document:  Meta-analysis of genome-wide association studies in African Americans provides insights into the gen...
Next Document:  Conversion From Child Psychotherapy to Child Analysis.